192 related articles for article (PubMed ID: 30865931)
1. NETest liquid biopsy is diagnostic of small intestine and pancreatic neuroendocrine tumors and correlates with imaging.
Malczewska A; Witkowska M; Makulik K; Bocian A; Walter A; Pilch-Kowalczyk J; Zajęcki W; Bodei L; Oberg KE; Kos-Kudła B
Endocr Connect; 2019 Mar; 8(4):442-53. PubMed ID: 30865931
[TBL] [Abstract][Full Text] [Related]
2. Prospective Evaluation of the NETest as a Liquid Biopsy for Gastroenteropancreatic and Bronchopulmonary Neuroendocrine Tumors: An ENETS Center of Excellence Experience.
Malczewska A; Witkowska M; Wójcik-Giertuga M; Kuśnierz K; Bocian A; Walter A; Rydel M; Robek A; Pierzchała S; Malczewska M; Leś-Zielińska I; Czyżewski D; Ziora D; Pilch-Kowalczyk J; Zajęcki W; Kos-Kudła B
Neuroendocrinology; 2021; 111(4):304-319. PubMed ID: 32335553
[TBL] [Abstract][Full Text] [Related]
3. The NETest liquid biopsy is diagnostic for gastric neuroendocrine tumors: observations on the blood-based identification of microscopic and macroscopic residual diseaseOK.
Malczewska A; Procner A; Walter A; Kusnierz K; Zajecki W; Aslanian H; Kos-Kudla B
BMC Gastroenterol; 2020 Jul; 20(1):235. PubMed ID: 32703157
[TBL] [Abstract][Full Text] [Related]
4. A multigenomic liquid biopsy biomarker for neuroendocrine tumor disease outperforms CgA and has surgical and clinical utility.
Modlin IM; Kidd M; Falconi M; Filosso PL; Frilling A; Malczewska A; Toumpanakis C; Valk G; Pacak K; Bodei L; Öberg KE
Ann Oncol; 2021 Nov; 32(11):1425-1433. PubMed ID: 34390828
[TBL] [Abstract][Full Text] [Related]
5. Circulating Transcript Analysis (NETest) in GEP-NETs Treated With Somatostatin Analogs Defines Therapy.
Ćwikła JB; Bodei L; Kolasinska-Ćwikła A; Sankowski A; Modlin IM; Kidd M
J Clin Endocrinol Metab; 2015 Nov; 100(11):E1437-45. PubMed ID: 26348352
[TBL] [Abstract][Full Text] [Related]
6. NET Blood Transcript Analysis Defines the Crossing of the Clinical Rubicon: When Stable Disease Becomes Progressive.
Pavel M; Jann H; Prasad V; Drozdov I; Modlin IM; Kidd M
Neuroendocrinology; 2017; 104(2):170-182. PubMed ID: 27078712
[TBL] [Abstract][Full Text] [Related]
7. Assessment of NETest Clinical Utility in a U.S. Registry-Based Study.
Liu E; Paulson S; Gulati A; Freudman J; Grosh W; Kafer S; Wickremesinghe PC; Salem RR; Bodei L
Oncologist; 2019 Jun; 24(6):783-790. PubMed ID: 30158287
[TBL] [Abstract][Full Text] [Related]
8. Early Identification of Residual Disease After Neuroendocrine Tumor Resection Using a Liquid Biopsy Multigenomic mRNA Signature (NETest).
Modlin IM; Kidd M; Oberg K; Falconi M; Filosso PL; Frilling A; Malczewska A; Salem R; Toumpanakis C; Laskaratos FM; Partelli S; Roffinella M; von Arx C; Kudla BK; Bodei L; Drozdov IA; Kitz A
Ann Surg Oncol; 2021 Nov; 28(12):7506-7517. PubMed ID: 34008138
[TBL] [Abstract][Full Text] [Related]
9. Blood mRNA Measurement (NETest) for Neuroendocrine Tumor Diagnosis of Image-Negative Liver Metastatic Disease.
Malczewska A; Bodei L; Kidd M; Modlin IM
J Clin Endocrinol Metab; 2019 Mar; 104(3):867-872. PubMed ID: 30358858
[TBL] [Abstract][Full Text] [Related]
10. The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract.
Modlin IM; Kidd M; Bodei L; Drozdov I; Aslanian H
Am J Gastroenterol; 2015 Aug; 110(8):1223-32. PubMed ID: 26032155
[TBL] [Abstract][Full Text] [Related]
11. Blood Molecular Genomic Analysis Predicts the Disease Course of Gastroenteropancreatic Neuroendocrine Tumor Patients: A Validation Study of the Predictive Value of the NETest®.
van Treijen MJC; van der Zee D; Heeres BC; Staal FCR; Vriens MR; Saveur LJ; Verbeek WHM; Korse CM; Maas M; Valk GD; Tesselaar MET
Neuroendocrinology; 2021; 111(6):586-598. PubMed ID: 32492680
[TBL] [Abstract][Full Text] [Related]
12. A novel liquid biopsy (NETest) identifies paragangliomas and pheochromocytomas with high accuracy.
Pacak K; Kidd M; Meuter L; Modlin IM
Endocr Relat Cancer; 2021 Oct; 28(11):731-744. PubMed ID: 34515661
[TBL] [Abstract][Full Text] [Related]
13. NETest is superior to chromogranin A in neuroendocrine neoplasia: a prospective ENETS CoE analysis.
Malczewska A; Oberg K; Kos-Kudla B
Endocr Connect; 2021 Jan; 10(1):110-123. PubMed ID: 33289691
[TBL] [Abstract][Full Text] [Related]
14. NETest Liquid Biopsy Is Diagnostic of Lung Neuroendocrine Tumors and Identifies Progressive Disease.
Malczewska A; Oberg K; Bodei L; Aslanian H; Lewczuk A; Filosso PL; Wójcik-Giertuga M; Rydel M; Zielińska-Leś I; Walter A; Suarez AL; Kolasińska-Ćwikła A; Roffinella M; Jamidar P; Ziora D; Czyżewski D; Kos-Kudła B; Ćwikła J
Neuroendocrinology; 2019; 108(3):219-231. PubMed ID: 30654372
[TBL] [Abstract][Full Text] [Related]
15. PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest.
Bodei L; Kidd MS; Singh A; van der Zwan WA; Severi S; Drozdov IA; Malczewska A; Baum RP; Kwekkeboom DJ; Paganelli G; Krenning EP; Modlin IM
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):895-906. PubMed ID: 31838581
[TBL] [Abstract][Full Text] [Related]
16. The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors.
Malczewska A; Kos-Kudła B; Kidd M; Drozdov I; Bodei L; Matar S; Oberg K; Modlin IM
Adv Med Sci; 2020 Mar; 65(1):18-29. PubMed ID: 31841822
[TBL] [Abstract][Full Text] [Related]
17. The Application of 68Ga-Somatostatin Analogue and 18F-FDG PET/CT for Bone Metastasis from Neuroendocrine Tumors.
Bai L; Xu J; Xu X; Zhang J; Liu X; Hu S; Chen J; Song S
Neuroendocrinology; 2024 Jun; ():. PubMed ID: 38824926
[TBL] [Abstract][Full Text] [Related]
18. Blood Transcript Profiling for the Detection of Neuroendocrine Tumors: Results of a Large Independent Validation Study.
van Treijen MJC; Korse CM; van Leeuwaarde RS; Saveur LJ; Vriens MR; Verbeek WHM; Tesselaar MET; Valk GD
Front Endocrinol (Lausanne); 2018; 9():740. PubMed ID: 30564197
[No Abstract] [Full Text] [Related]
19. The Combined Interpretation of 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT in Metastatic Gastroenteropancreatic Neuroendocrine Tumors: A Classification System With Prognostic Impact.
Hayes AR; Furtado O'Mahony L; Quigley AM; Gnanasegaran G; Caplin ME; Navalkissoor S; Toumpanakis C
Clin Nucl Med; 2022 Jan; 47(1):26-35. PubMed ID: 34874347
[TBL] [Abstract][Full Text] [Related]
20. Prediction of the aggressiveness of non-functional pancreatic neuroendocrine tumors based on the dual-tracer PET/CT.
Majala S; Seppänen H; Kemppainen J; Sundström J; Schalin-Jäntti C; Gullichsen R; Schildt J; Mustonen H; Vesterinen T; Arola J; Kauhanen S
EJNMMI Res; 2019 Dec; 9(1):116. PubMed ID: 31872324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]